CompletedPhase 3NCT02979899
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tracon Pharmaceuticals Inc.
- Principal Investigator
- Charles Theuer, MDTRACON Pharmaceuticals
- Intervention
- TRC105(biological)
- Enrollment
- 128 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2017 – 2019
Study locations (30)
- University of Arizona Cancer Center, Tucson, Arizona, United States
- Stanford University, Palo Alto, California, United States
- Sarcoma Oncology Center, Santa Monica, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Northside Hospital, Sandy Springs, Georgia, United States
- University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Washington University St. Louis, St Louis, Missouri, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Northwell Health, Lake Success, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02979899 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive